1
|
Hatipoğlu D, Mulligan C, Wang J, Peticco J, Grinspoon R, Gadi S, Mills C, Luther J, Chung RT. Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression. Gastro Hep Adv 2023; 2:480-486. [PMID: 36816340 PMCID: PMC9922433 DOI: 10.1016/j.gastha.2023.01.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 01/25/2023] [Accepted: 01/27/2023] [Indexed: 02/24/2023]
Abstract
Background and Aims Patients with chronic liver disease (CLD) were significantly affected by COVID-19. Despite evidence of acute hepatic injury and increased mortality, the long-term effects of COVID-19 hospitalization on the natural history of CLD patients is unknown. Methods The Massachusetts General Hospital COVID-19 registry was used to obtain a cohort of CLD patients hospitalized between March 8 and June 3, 2020. The Partners Research Patient Data Registry (RPDR) was used to develop a matched CLD patient control list without COVID-19. FIB-4, NAFLD Fibrosis score (NFS), and MELD-Na scores were calculated pre-, day of, and 1-year post-discharge from admission. Unpaired T-test was used to compare continuous variables. Results Fifty-two COVID-19 patients and 92 control patients with CLD were included. Patients with non-cirrhotic CLD who were hospitalized for COVID-19 had an acute rise in FIB-4 on admission with subsequent improvement on one year follow up demonstrating no difference in progression of liver disease compared to the controls (p = 0.87, CI -0.088 to 0.048). Similar trends were observed in NAFLD patients using NFS (p = 0.48, CI -0.016 to 0.023). In contrast, patients with cirrhosis experienced rise in MELD-Na post-admission compared to the control cirrhosis group (0.35 vs -0.076/month; p = 0.04, CI -0.827 to -0.025), suggesting a potential for long-term consequences of COVID-19. Conclusion Non-cirrhotic CLD patients who survive COVID-19 hospitalization do not appear to have change in FIB-4, NFS scores at one year. However, patients with cirrhosis exhibit increasing MELD-Na one-year post-COVID suggesting a differential effect of acute COVID-19 on the trajectory of established cirrhosis.
Collapse
Affiliation(s)
- Dilara Hatipoğlu
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Connor Mulligan
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Jeffrey Wang
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Juan Peticco
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | | | | | - Camilla Mills
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, USA
| | - Jay Luther
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Raymond T. Chung
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Correspondence: Raymond T. Chung, MD, Liver Center, GI Division, Massachusetts General Hospital, Boston, MA 02114
| |
Collapse
|